GleamWall
中文EN

NUVB Nuvation Bio Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1811063 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY654.2%
TTM net income YoY37.5%
TTM EPS YoY20.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-61.2%
Net margin-67.4%
FCF margin—
EBITDA margin-60.1%

Returns

ROE-49.1%
ROA-19.7%
ROIC (approx.)-30.5%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets70.7%
Debt / equity1.25x
Current ratio7.45x
Interest coverage-5.87x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$44.95M$31.69M$83.23M$41.87M$13.12M$4.83M$3.08M$5.71M
Cost of revenue————$3.35M$2.58M$2.09M$4.22M
Gross profit————$9.77M$2.26M$990,000$1.50M
R&D expense$32.68M$30.66M$35.05M$34.30M$28.85M$27.36M$24.60M$29.30M
SG&A expense$42.55M$42.59M$38.31M$40.33M$37.36M$38.48M$35.39M$26.14M
Operating income-$42.21M-$51.04M$3.88M-$34.04M-$56.43M-$63.59M-$59.00M-$53.94M
Interest expense$881,000$6.76M$6.71M$6.67M$5.12M$421,000$54,000$89,000
Pretax income-$41.90M-$62.84M$5.40M-$36.59M-$55.79M-$59.01M-$53.24M-$49.45M
Income tax$0$0$0$0$0$0$0$0
Net income-$41.90M-$62.84M$5.40M-$36.59M-$55.79M-$59.01M-$53.24M-$49.45M
EBITDA-$41.63M-$50.50M$4.42M-$33.50M-$55.90M-$63.23M-$58.69M-$53.72M
EPS (basic)-0.12-0.180.02—-0.16-0.17-0.16—
EPS (diluted)-0.12-0.180.01—-0.16-0.17-0.16—
Weighted avg. shares (diluted)351,861348,770377,521—342,393340,746338,612—
Balance sheet
Cash & equivalents$153.77M$258.60M$125.39M$164.09M$98.90M$247.97M$47.98M$35.72M
Short-term investments$509.60M$402.35M$408.34M$365.12M$450.15M$359.75M$413.70M$466.97M
Inventory$15.34M$19.90M$15.84M$11.41M$5.71M$552,000$14,000$0
Current assets$734.66M$726.43M$591.53M$571.52M$577.53M$623.21M$475.57M$526.25M
PP&E, net$2.22M$715,000$535,000$564,000$560,000$615,000$562,000$586,000
Intangibles$19.80M$10.29M$10.76M$11.21M$11.68M$12.14M$4.41M$4.62M
Total assets$778.39M$744.50M$610.24M$594.82M$601.56M$647.23M$492.49M$540.63M
Current liabilities$98.56M$86.75M$79.52M$82.23M$68.13M$66.36M$52.77M$58.24M
Short-term debt$5.97M$5.89M$5.79M$5.72M$5.62M$5.58M$5.68M$6.28M
Long-term debt$279.46M$242.62M$47.33M$47.21M$47.09M$46.97M——
Total debt$285.43M$248.52M$53.12M$52.93M$52.71M$52.56M——
Total liabilities$550.42M$490.64M$290.68M$289.11M$275.68M$274.32M$73.03M$76.84M
Shareholders' equity$227.97M$253.86M$319.56M$305.72M$325.88M$372.91M$419.46M$463.79M
Net debt$131.66M-$10.09M-$72.27M-$111.15M-$46.19M-$195.41M——
Shares outstanding346.50M346.50M346.50M346.50M337.84M337.84M337.84M337.84M
Cash flow statement
Operating cash flow-$38.56M-$42.97M$5.07M-$29.73M-$52.89M-$48.18M-$42.63M-$46.30M
Capital expenditure———$0———$0
Free cash flow———-$29.73M———-$46.30M
Investing cash flow-$109.34M$5.99M-$43.64M$87.08M-$96.62M$54.88M$54.18M$51.77M
Financing cash flow$43.16M$170.53M$44,000$8.06M$501,000$193.42M$548,000-$900,000
Depreciation & amortization$578,000$536,000$536,000$539,000$534,000$356,000$310,000$219,000
Stock-based compensation$10.07M$10.46M$9.03M$7.99M$8.02M$12.03M$7.85M$10.19M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.